Carboplatin Alone vs Carboplatin plus Epidoxorubicin as Second-Line Therapy for Cisplatin- or Carboplatin-Sensitive Ovarian Cancer
- 1 April 2001
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 81 (1) , 3-9
- https://doi.org/10.1006/gyno.2001.6151
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Paclitaxel vs Epidoxorubicin plus Paclitaxel as Second-Line Therapy for Platinum-Refractory and -Resistant Ovarian CancerGynecologic Oncology, 1999
- Paclitaxel–Anthracycline Combination Chemotherapy in Relapsing Advanced Ovarian Cancer after Platinum-Based Chemotherapy: A Pilot StudyGynecologic Oncology, 1998
- Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma.Journal of Clinical Oncology, 1998
- Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinomaAnnals of Oncology, 1998
- Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer.Journal of Clinical Oncology, 1997
- Cancer of the OvaryNew England Journal of Medicine, 1993
- Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.Journal of Clinical Oncology, 1991
- Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compoundsGynecologic Oncology, 1990
- Reporting results of cancer treatmentCancer, 1981
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977